

July 15, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To, Glenmark Life Sciences Limited Plot No 170-172 Chandramouli Industrial Estate Mohol Bazarpeth, Solapur 413 213

Dear Sir/Madam,

To,
The Manager – Listing
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

**Ref: Scrip Name: GLENMARK** 

Sub: Disclosure under Regulation 31(2) read with Regulation 28(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Pursuant to Regulation 31(2) read with Regulation 28(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as prescribed pursuant to the Master Circular for Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, bearing reference no. SEBI/HO/CDF/PoD-1/P/CIR/2023/31, dated February 16, 2023, please find attached disclosure in relation to the shares of Glenmark Life Sciences Limited in **Annexure A**.

This is for your information and records.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber

Company Secretary & Compliance Officer

Encl: As above



## Annexure A

Disclosure by the Promoter to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of Target Company (TC)	et Compan	v (TC)					Glenmark Li	Glenmark Life Sciences Limited ("GLS")	mited ("GI	S")			
Names of the stock exchanges where the shares of the target company are listed	stock excha	anges wi	here the sh	ares of	the target c	ompany are	BSE Limited	BSE Limited and National Stock Exchange of India Limited	Stock Exch	nange of	India Limitec		
Date of reporting	ing						July 15, 2024	4					
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked	romoter or ed/invoked	PAC or	whose sha	res enc	umbrance l	nas been	Glenmark Pl	Glenmark Pharmaceuticals Limited ("GPL"	Limited ("	GPL")			
Details of the creation of encumbrance:	creation of	encumb	rance:										
Name of the	Promoter holding in the	n the	Promoter holding already	lready	Details of	Details of events pertaining to encumbrance (3)	ning to encum	brance (3)				Post event holding of	of of
promoter (s) or PACs	target company (1)	mpany	encumbered (2)	ed (2)								encumbered shares {creation	n
PACs with												{creation [(2)+(3)] / release	n  -/  (2)-
												(3)]	
												/ invocation [(1)-(3)]]	tion
	Number	% of	Number	% of	Type of	Date of	Type of	Reasons for	Number	% of	Name of	Numb	% of
		total		total	event	creation/	encumbran	encumbran		total	the entity	er	total
		share		share	(creation	release/	ce	се		share	Ð.		share
		capit		capit	1	invocation	(pledge/			capit	whose		capit
		<u>a</u>		al	release /	of	lien/			al	favor		al
					invocatio	encumbran	non				shares		
					n)	се	disposal undertakin				encumber ed		
							g/ others)						
Glenmark Pharmaceutic als Limited	96,09,5 71	7.84 %	96,09,5 71	7.84 %	Release	July 4, 2024	Non- Disposal Undertakin	The non- disposal undertakin	96,09,5 71	7.84 %	Nirma Limited	Z:	Z
[(including its							(to)	g was					
nominee								waived					
]*								execution					
								of the letter					

					20										
					_							_	_	_	
Limited ("SPA").	and Nirma	among	21, 2023	September	dated	agreement	purchase	the share	amending	t") for	Agreemen	("Letter	4, 2024	dated July	agreement
								_							
												=			

Signature of Authorised Signatory

Place: Mumbai Date: July 15, 2024

V.S. Mani

Executive Director and Global Chief Financial Officer